secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0000950170-25-072603
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health Q1 revenue drops 79% to $70K; pursues Entolimod and ncVNS pipeline
-------------------------------------------------------------------------------

- Revenue fell 79% YoY to $70K; net loss unchanged at $1.5M. Cash $669K vs $2.0M at year-end.
- Licensed Phase III TLR5 agonist Entolimod for ARS; began GMP manufacturing validation for BLA.
- Briefed White House and FDA on defense applications; secured $25M equity line and $8.4M purchase agreement.
- Expanded ncVNS optimization study; regained Nasdaq compliance via 1-for-17 reverse split in March.
- Gross margin improved to 72% (vs 50% a year ago) but operating expenses flat at $1.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025072603/0000950170-25-072603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025072603/tivc-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-072603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer